Not sure if this has been posted already or not, but drug company MSD recently acquired a medical drug company EyeBio which develops a drug to treat DME (diabetic macular oedema). 1.3 Bn USD upfront and up to addtional 1.7 Bn USD in milestone payments.
https://www.msd.com/news/msd-to-acquire-eyebio/
This seems the same field (disease) that 2RT is currently authorized in Europe (if I am not mistaken): https://simovision.com/assets/Uploads/Brochure-Ellex-2RT-EN.pdf
Seems like a positive event, which I think signifies how undervalued NovaEye is - not only in the iTrack front, but also in the 2RT side which seems to get no valuation at all.
- Forums
- ASX - By Stock
- EYE Summary (August 2024): Incredibly Undervalued
Not sure if this has been posted already or not, but drug...
Featured News
Add EYE (ASX) to my watchlist
|
|||||
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $48.10M |
Open | High | Low | Value | Volume |
21.0¢ | 21.5¢ | 21.0¢ | $45.70K | 217.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2722 | 21.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
21.5¢ | 57356 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2722 | 0.210 |
4 | 112267 | 0.205 |
18 | 268350 | 0.200 |
1 | 100000 | 0.195 |
1 | 52636 | 0.190 |
Price($) | Vol. | No. |
---|---|---|
0.215 | 57356 | 2 |
0.225 | 43209 | 2 |
0.230 | 103718 | 2 |
0.235 | 20000 | 1 |
0.240 | 30796 | 2 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
EYE (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online